Owners, management and financials
CVR: 40868151
DKK 3,743,522
Revenue
Net result: DKK 706,595
ARXX THERAPEUTICS AS (100%)
CVR · view owners
Berte Aagot Hedding Poulsson, Jonas Hallén
CVR · view management
Active
Founded 1 October 2019
CVR · view overview
No headcount reported
Director registered: Jonas Hallén
CVR · 14/08/2025
View the full event history
ARXX Therapeutics ApS is a Danish company of the type Anpartsselskab based in Herlev, founded in 2019. The company is registered under the industry Fremstilling af farmaceutiske præparater. The management consists of Berte Aagot Hedding Poulsson and Jonas Hallén. The company is owned by ARXX THERAPEUTICS AS. In 2025, the company reported revenue of DKK 3,743,522 and a net result of DKK 706,595 compared with DKK 116,729 the year before. Equity in the 2025 report amounted to DKK 1,688,804.
Source: annual report 2025, Danish Business Authority
ARXX Therapeutics ApS has demonstrated a positive trajectory in financial health, with revenue increasing from 2.6 million DKK in 2024 to 3.7 million DKK in 2025, alongside a significant rise in profit from 116,729 DKK to 706,595 DKK. The company has shown resilience despite a dip in revenue in 2023 compared to 2022, indicating potential volatility in sales. Notably, equity has improved markedly from 177,355 DKK in 2021 to 1,688,804 DKK in 2025, reflecting a strengthening balance sheet. However, the fluctuating revenue and profit margins suggest a need for strategic stability as the company navigates the competitive pharmaceutical manufacturing industry.
AI-generated summary · Generated 14/04/2026
Selskabets formål er at udvikle, markedsføre og sælge lægemidler samt al virksomhed, som efter direktionens skøn er beslægtet hermed
Source: annual reports filed with the Danish Business Authority.
| Period | Revenue | Profit/Loss | Total Assets | Equity | Employees | Report |
|---|---|---|---|---|---|---|
| 202501/01/2025 – 31/12/2025 | 3.7 mio. | 707 t. | 1.9 mio. | 1.7 mio. | - | |
| 202401/01/2024 – 31/12/2024 | 2.6 mio. | 117 t. | 1.4 mio. | 982 t. | - | |
| 202301/01/2023 – 31/12/2023 | 2.8 mio. | 270 t. | 1.2 mio. | 865 t. | - | |
| 202201/01/2022 – 31/12/2022 | 5.8 mio. | 507 t. | 1.2 mio. | 596 t. | - | |
| 202101/01/2021 – 31/12/2021 | 2.4 mio. | 77 t. | 729 t. | 177 t. | - |
Compared to 128 companies in Fremstilling af farmaceutiske præparater
Comparison is based on industry median values
Screen owners and management against the Danish FSA's official PEP lists
Get notified instantly about new financial statements, ownership changes, management changes and status changes.
Set up monitoringThe CVR number of ARXX Therapeutics ApS is 40868151.
ARXX Therapeutics ApS is owned by ARXX THERAPEUTICS AS.
The management of ARXX Therapeutics ApS consists of Berte Aagot Hedding Poulsson and Jonas Hallén.
In 2025, ARXX Therapeutics ApS reported revenue of DKK 3,743,522.
ARXX Therapeutics ApS was founded on 1 October 2019.
ARXX Therapeutics ApS is registered under the industry Fremstilling af farmaceutiske præparater (industry code 212000).
Claim this page to add your logo and social links. Free to get started.
ARXX Therapeutics ApS has published its annual report for 2025. Revenue came to DKK 3,743,522, and the net result was DKK 706,595.
As of August 14, 2025, Farzad Abdi-Dezfuli has left the board of directors of ARXX Therapeutics ApS.
As of August 14, 2025, Jonas Hallén has left the board of directors of ARXX Therapeutics ApS.
As of August 14, 2025, Susanne Stuffers has left the board of directors of ARXX Therapeutics ApS.
As of August 14, 2025, Jonas Hallén is registered as director of ARXX Therapeutics ApS.
As of August 14, 2025, Berte Aagot Hedding Poulsson is registered as director of ARXX Therapeutics ApS.
As of August 14, 2025, Susanne Stuffers has stepped down as director of ARXX Therapeutics ApS.
ARXX Therapeutics ApS has published its annual report for 2024. Revenue came to DKK 2,608,206, and the net result was DKK 116,729.
ARXX Therapeutics ApS has published its annual report for 2023. Revenue came to DKK 2,790,576, and the net result was DKK 269,759.
ARXX Therapeutics ApS has published its annual report for 2022. Revenue came to DKK 5,789,922, and the net result was DKK 507,105.
ARXX Therapeutics ApS has published its annual report for 2021. Revenue came to DKK 2,396,646, and the net result was DKK 77,355.
ARXX Therapeutics ApS has published its interim report for the period October 1, 2019 – December 31, 2020.
As of October 1, 2019, Farzad Abdi-Dezfuli has joined the board of directors of ARXX Therapeutics ApS.
As of October 1, 2019, Jonas Hallén has joined the board of directors of ARXX Therapeutics ApS.
As of October 1, 2019, Susanne Stuffers has joined the board of directors of ARXX Therapeutics ApS.
As of October 1, 2019, Susanne Stuffers is registered as director of ARXX Therapeutics ApS.
As of October 1, 2019, is registered as an owner of ARXX Therapeutics ApS with an ownership share of 100%.
ARXX Therapeutics ApS was founded on October 1, 2019.
Companies in the same industry and area
CVR 39038323
CVR 33155131
CVR 41407352
CVR 45480941
CVR 26411238
